A prospective RCT in adult patients with CF showed a trend towards shorter time to first exacerbation and increased number of exacerbations over a 6-month period in patients receiving esomeprazole compared with placebo, but the small sample size of this study precludes generalisability of the results [ 138 ].
← all excerpts
Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review.
1
—
—